HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Hyperprolactinemia — Clinical Guidelines

Overview

Hyperprolactinemia is characterized by elevated levels of prolactin in the blood, often leading to various clinical manifestations including menstrual irregularities, infertility, and galactorrhea. It can result from both physiological and pathological conditions, including medication side effects and pituitary disorders 1 2 6 8.

Diagnosis

Measure serum prolactin levels to confirm hyperprolactinemia.

Differentiate between macroprolactinemia and hyperprolactinemia using specific assays to avoid unnecessary investigations 1.

Evaluate for clinical symptoms such as amenorrhea, galactorrhea, and infertility.

Consider imaging studies (e.g., MRI of the pituitary) if organic causes are suspected 12.

Management

First-line treatments: Dopamine agonists such as cabergoline or bromocriptine are typically used 3 12.

Adjunctive management: Address underlying causes (e.g., discontinuation of offending medications like clomipramine or omeprazole 8 6).

Vitamin D supplementation: Consider in patients with concurrent vitamin D deficiency to potentially mitigate cardiometabolic risks 3.

Special Populations

Pediatrics: Hyperprolactinemia in children, such as induced by omeprazole, requires prompt recognition and management 6.

Comorbidities: In patients with vitamin D deficiency, monitor and manage vitamin D status alongside prolactin-lowering therapies 3.

Key Recommendations

Utilize specific prolactin assays to distinguish between macroprolactinemia and hyperprolactinemia to guide appropriate management 1 (Evidence: Strong).

Initiate treatment with dopamine agonists like cabergoline or bromocriptine for symptomatic hyperprolactinemia 12 (Evidence: Strong).

Evaluate and address potential drug-induced hyperprolactinemia by reviewing patient medication lists 2 6 8 (Evidence: Moderate).

Consider vitamin D status in women with hyperprolactinemia and manage accordingly to optimize cardiometabolic health 3 (Evidence: Moderate).

References

1 Glezer A, Elias PCL, Nogueira VDSN, Garmes HM, Kasuki L, Rollin GAFS et al.. Position statement on macroprolactinemia from the Department of Neuroendocrinology of the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society of Clinical Pathology/Laboratory Medicine (SBPC/ML). Archives of endocrinology and metabolism 2025. link 2 Liu J, Xue L, Fang X, Zheng C, Zeng F, Liu Y et al.. Drug-associated hyperprolactinemia: A comprehensive disproportionality analysis based on the FAERS database. European journal of pharmacology 2025. link 3 Krysiak R, Basiak M, Machnik G, Szkróbka W, Okopień B. Vitamin D Status Determines Cardiometabolic Effects of Cabergoline in Women with Elevated Prolactin Levels: A Pilot Study. Nutrients 2023. link 4 Singhania P, Bhattarcharjee R, Chowdhury S. Van Wyk-Grumbach syndrome: a rare presentation of a common endocrine disorder. Endokrynologia Polska 2022. link 5 Ferreira AG, Scherer EB, da Cunha AA, Manfredini V, Biancini GB, Vanzin CS et al.. Hyperprolinemia induces DNA, protein and lipid damage in blood of rats: antioxidant protection. The international journal of biochemistry & cell biology 2014. link 6 Jabbar A, Khan R, Farrukh SN. Hyperprolactinaemia induced by proton pump inhibitor. JPMA. The Journal of the Pakistan Medical Association 2010. link 7 Rego MD, Giller EL. Mania secondary to amantadine treatment of neuroleptic-induced hyperprolactinemia. The Journal of clinical psychiatry 1989. link 8 Fowlie S, Burton J. Hyperprolactinaemia and nonpuerperal lactation associated with clomipramine. Scottish medical journal 1987. link 9 Lloyd RV, Landefeld TD. Detection of prolactin messenger RNA in rat anterior pituitary by in situ hybridization. The American journal of pathology 1986. link 10 Macnamee MC, Sharp PJ, Lea RW, Sterling RJ, Harvey S. Evidence that vasoactive intestinal polypeptide is a physiological prolactin-releasing factor in the bantam hen. General and comparative endocrinology 1986. link90057-2) 11 Jackson RD, Wortsman J, Malarkey WB. Characterization of a large molecular weight prolactin in women with idiopathic hyperprolactinemia and normal menses. The Journal of clinical endocrinology and metabolism 1985. link 12 Gangemi M. Hyperprolactinemic amenorrhea. Clinical and experimental obstetrics & gynecology 1984. link 13 Schreiber V, Dusková J, Pribyl T, Svobodová V, Jahodová J. Metoclopramide potentiates the hypophyseal reactions to oestradiol. Physiologia Bohemoslovaca 1984. link

Hyperprolactinemia